We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04965337
Previous Study | Return to List | Next Study

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04965337
Recruitment Status : Completed
First Posted : July 16, 2021
Last Update Posted : June 30, 2022
Sponsor:
Information provided by (Responsible Party):
Ascletis Pharmaceuticals Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: ASC42 Drug: Placebo Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Other
Official Title: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects
Actual Study Start Date : July 11, 2021
Actual Primary Completion Date : August 1, 2021
Actual Study Completion Date : August 1, 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ASC42 Dose A
ASC42 tablet Dose A, once daily
 Drug: ASC42
ASC42 tablet administered orally
Placebo Comparator: Placebo Dose A
Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
 Drug: Placebo
Matching placebo administered orally
Experimental: ASC42 Dose B
ASC42 tablet Dose B, once daily
 Drug: ASC42
ASC42 tablet administered orally
Placebo Comparator: Placebo Dose B
Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
 Drug: Placebo
Matching placebo administered orally


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. AUC of ASC42 [ Time Frame: Up to 4 days ]
    Evaluate the Area under the plasma concentration versus time curve.

  2. Cmax of ASC42 [ Time Frame: Up to 4 days ]
    Evaluate the Peak Plasma Concentration.


Secondary Outcome Measures :
  1. t1/2 of ASC42 [ Time Frame: Up to 4 days ]
    Evaluate the Terminal-Phase Half-Life.

  2. CL/F of ASC42 [ Time Frame: Up to 4 days ]
    Evaluate the Apparent Systemic Clearance.

  3. Vd/F of ASC42 [ Time Frame: Up to 4 days ]
    Evaluate the Apparent Volume of Distribution.

  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Up to 7 days ]
    Occurrence of Serious Adverse Event (SAE), Adverse Event (AE) resulting in treatment discontinuation and/or dose reductions, and AE of special interest, from baseline up to 7 days.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Healthy male and female volunteers aged 18-55 years.
  • 19kg/m2 ≤ BMI <24kg/m2.

Key Exclusion Criteria:

  • A positive HBsAg, HCV Ab and/or HIV Ab.
  • Pancreatic injury or pancreatitis.
  • History of organ transplantation, including bone marrow transplantation.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04965337


Locations
Layout table for location information
China, Hunan
Xiangya Boai Rehabilitation Hospital
Changsha, Hunan, China, 410008
Sponsors and Collaborators
Ascletis Pharmaceuticals Co., Ltd.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Ascletis Pharmaceuticals Co., Ltd.
ClinicalTrials.gov Identifier: NCT04965337    
Other Study ID Numbers: ASC42-102
First Posted: July 16, 2021    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ascletis Pharmaceuticals Co., Ltd.:
Healthy Subjects
ASC42
FXR agonist